%0 Journal Article
%T Impact of Primary Disease Site of Involvement by Early-Stage Follicular Lymphoma on Patient Outcomes.
%A Davis O
%A Lessani C
%A Kasht R
%A Cohoon A
%A Ibrahimi S
%A Asch A
%A Day S
%A Al-Juhaishi T
%J Clin Lymphoma Myeloma Leuk
%V 0
%N 0
%D 2024 Jul 15
%M 39147647
%F 2.822
%R 10.1016/j.clml.2024.07.012
%X <B>BACKGROUND: </B>Follicular lymphoma is a common non-Hodgkin lymphoma that can start in a diverse array of tissues throughout the body. While the majority of patients may be able to live many years with this disease, cure remains very difficult to achieve.<BR><B>OBJECTIVE: </B>We sought to investigate the impact of follicular lymphoma primary disease site in early-stage disease on patient outcomes using a large national database.<BR><B>METHODS: </B>Baseline demographic and disease data for patients diagnosed with follicular lymphoma from 2000-2015 was identified and extracted from the NCI Surveillance, Epidemiology, and End Results (SEER) database. Primary disease sites were grouped into one of two cohorts: nodal disease (lymph nodes and spleen) and extranodal disease (everything else). Analysis was performed using summary statistics, Kaplan-Meier method, and Cox-proportional hazards models for univariate and multivariate analysis.<BR><B>RESULTS: </B>A total of 13,400 patients were included in the final analysis and the majority were non-Hispanic white (81%), with stage I (63%), and nodal FL (79%). Median overall survival for nodal disease was 15.1 years [95% CI (14.6-15.6)] while median overall survival for extranodal disease was 15.8 years [95% CI (14.9-16.3)]. Overall survival was slightly better for patients with extranodal disease [HR = 0.89, 95% CI (0.84-0.96); p-value = 0.00012]. This finding remained consistent after controlling for age and race [HR = 0.84, 95% CI (0.79-0.90); p-value <0.0001].<BR><B>CONCLUSIONS: </B>The primary site of involvement by early-stage follicular lymphoma may have an impact on patient outcomes and warrants further investigation.